<DOC>
	<DOCNO>NCT01010646</DOCNO>
	<brief_summary>Three-parallel-arm , open-label , international ( France Romania ) study , compare three treatment The purpose study confirm IFN alfa-2b XL well antiviral activity tolerability compare current market reference , combine ribavirin , 3-month therapy setting .</brief_summary>
	<brief_title>Study Comparing Tolerability Viral Reduction Combination IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin Patients With Chronic Hepatitis C , Genotype 1 4</brief_title>
	<detailed_description>Interferon alfa-2b XL ( IFN alfa-2b XL ) novel sustain release interferon α-2b drug product develop FLAMEL TECHNOLOGIES use Medusa® technology , aim reduce toxicity enhance biological response . In present study , patient randomly assign either IFN alfa-2b XL 27 MUI , IFN alfa-2b XL 36 MUI , IFN peg alfa-2b 1.5 µg/kg , administer week 12 week subcutaneous injection , combination weight dose ribavirin daily administer orally two divided dos . Doses adapt accord dose modification guideline combination therapy label ribavirin prescribe information .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patient voluntarily sign Informed Consent Form prior study specific procedure perform Male female HCV genotype 1 4 infected patient ( positive serum HCV RNA ) , age 18 65 year inclusive , body mass within range equal 45Kg equal 100 Kg Patient either naïve therapy , either nonresponder previous standard Peginterferon α + ribavirin therapy , With absolute contraindication interferon α ribavirin Female patient must nonlactating nonchildbearing potential , negative pregnancy test result enter study No evidence acute advance liver disease , uncontrolled diabetes , cardiovascular , immunological , thyroid disease , recently diagnose malignancy Vital sign within normal range , outside normal range , deem clinically significant opinion Investigator . An ECG clinically significant abnormality History solid organ transplantation Severe systemic infection , uncontrolled diabetes , cancer , associate liver disease General anesthesia recent blood transfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>hepatitis C</keyword>
	<keyword>viral kinetics</keyword>
	<keyword>antiviral response</keyword>
	<keyword>Genotype 1 4</keyword>
</DOC>